Thyrocare Technologies has reported strong financial results for the quarter and financial year ended March 31, 2026. The company achieved a 20% YoY increase in consolidated revenue for Q4FY26 and a 21% YoY growth for the full fiscal year. Reported EBITDA surged by 38% YoY in FY26, with profit after tax rising by 81% YoY, highlighting the company’s commitment to delivering high-quality, accessible, and affordable diagnostic services nationwide.
FY26 Financial and Operational Highlights
Thyrocare concluded the fiscal year 2026 with consistent growth across all key metrics. For the full year, the company reported consolidated revenue of ₹829 crore, a 21% increase over the previous year. The standalone pathology business was a significant contributor, reaching ₹774 crore in revenue. Reported EBITDA for FY26 stood at ₹262.04 crore, reflecting a strong 38% growth, while the Profit After Tax (PAT) grew significantly by 81% to ₹162.85 crore.
Operational Expansion and Quality Standards
The company continued its aggressive network expansion, reaching a record high of ~10,800 active franchisees by the end of Q4FY26. This network growth is supported by a robust infrastructure of 40 labs across India and one international lab in Tanzania. Quality remains a core pillar, with 96% of samples processed in NABL-accredited labs and a notable 51% reduction in complaints per million tests compared to the previous year.
Strategic Initiatives
Thyrocare’s focus remains on leveraging a B2B service provider model centered on scale efficiencies. The company has successfully expanded its service offerings, introducing 1,275 tests—a 39% increase—incorporating advanced technologies like Next Gen sequencing, ImmunoCAP, and BioFire Panels. Additionally, the brand strengthened its presence by onboarding Madhuri Dixit as a brand ambassador and receiving national recognition at the Voice of Healthcare Forum.
Future Growth Pillars
Looking ahead, Thyrocare is prioritizing three strategic pillars to sustain its momentum: deepening its footprint in India with a focused test menu, expanding partnerships into insurance and ECG-at-home segments, and strengthening its international presence in Tanzania to ensure high-quality diagnostics remain accessible and affordable for all.
Source: BSE
